X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs CADILA HEALTHCARE - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD CADILA HEALTHCARE STRIDES SHASUN LTD/
CADILA HEALTHCARE
 
P/E (TTM) x 43.4 20.1 215.8% View Chart
P/BV x 1.1 4.8 22.6% View Chart
Dividend Yield % 0.9 0.9 106.8%  

Financials

 STRIDES SHASUN LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
CADILA HEALTHCARE
Mar-18
STRIDES SHASUN LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,275558 228.4%   
Low Rs918362 253.9%   
Sales per share (Unadj.) Rs389.6116.3 335.0%  
Earnings per share (Unadj.) Rs28.017.9 156.5%  
Cash flow per share (Unadj.) Rs48.923.1 211.4%  
Dividends per share (Unadj.) Rs4.503.50 128.6%  
Dividend yield (eoy) %0.40.8 53.9%  
Book value per share (Unadj.) Rs303.185.4 354.9%  
Shares outstanding (eoy) m89.421,023.74 8.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.0 71.2%   
Avg P/E ratio x39.225.7 152.3%  
P/CF ratio (eoy) x22.419.9 112.8%  
Price / Book Value ratio x3.65.4 67.2%  
Dividend payout %16.119.6 82.1%   
Avg Mkt Cap Rs m98,036470,664 20.8%   
No. of employees `0005.811.8 49.1%   
Total wages/salary Rs m5,88118,545 31.7%   
Avg. sales/employee Rs Th6,005.910,072.7 59.6%   
Avg. wages/employee Rs Th1,014.01,569.1 64.6%   
Avg. net profit/employee Rs Th431.21,547.7 27.9%   
INCOME DATA
Net Sales Rs m34,834119,049 29.3%  
Other income Rs m1,6861,132 148.9%   
Total revenues Rs m36,520120,181 30.4%   
Gross profit Rs m6,42828,475 22.6%  
Depreciation Rs m1,8725,388 34.7%   
Interest Rs m2,269911 249.1%   
Profit before tax Rs m3,97323,308 17.0%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m4705,644 8.3%   
Profit after tax Rs m2,50118,292 13.7%  
Gross profit margin %18.523.9 77.1%  
Effective tax rate %11.824.2 48.9%   
Net profit margin %7.215.4 46.7%  
BALANCE SHEET DATA
Current assets Rs m38,16582,005 46.5%   
Current liabilities Rs m30,40260,720 50.1%   
Net working cap to sales %22.317.9 124.6%  
Current ratio x1.31.4 93.0%  
Inventory Days Days7773 105.7%  
Debtors Days Days10498 106.3%  
Net fixed assets Rs m37,63983,703 45.0%   
Share capital Rs m8941,024 87.3%   
"Free" reserves Rs m26,21086,421 30.3%   
Net worth Rs m27,10587,445 31.0%   
Long term debt Rs m16,37725,551 64.1%   
Total assets Rs m81,168180,653 44.9%  
Interest coverage x2.826.6 10.3%   
Debt to equity ratio x0.60.3 206.8%  
Sales to assets ratio x0.40.7 65.1%   
Return on assets %5.910.6 55.3%  
Return on equity %9.220.9 44.1%  
Return on capital %12.122.0 54.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,46542,683 31.5%   
Fx outflow Rs m4,07611,242 36.3%   
Net fx Rs m9,38931,441 29.9%   
CASH FLOW
From Operations Rs m2,8819,193 31.3%  
From Investments Rs m-7,051-9,737 72.4%  
From Financial Activity Rs m3,382515 656.7%  
Net Cashflow Rs m-788-29 2,715.7%  

Share Holding

Indian Promoters % 27.7 74.8 37.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 8.3 455.4%  
FIIs % 8.6 5.9 145.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 11.0 235.5%  
Shareholders   56,241 44,069 127.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   SUVEN LIFE  SUN PHARMA  PIRAMAL ENTERPRISES  TORRENT PHARMA  DR. DATSONS LABS  

Compare STRIDES SHASUN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Sep 19, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 5-YR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS